$PayPal (PYPL.US)$ will it drop to 170-180 as what I read from a post? hopely not

$PayPal (PYPL.US)$ where were these guys when the stock was trading over 300😂
https://www.moomoo.com/en-us/news/post/6830703/is-paypal-s-stock-overvalued-or-undervalued-?src=2&futusource=news_stock_stockpagenews&report_type=stock&report_id=11804685&skintype=3&main_broker=WwogIDEwMDgKXQ==&level=1&data_ticket=1637681407477906

$IBM Corp (IBM.US)$ no matter what they announced, it’s becoming a new norm to expect quite the opposite in the market as against what should really have happened based on the news! recent announcements and performance results are classic examples including of Palantir Technologies🤐
any logic - No Logic!

$PayPal (PYPL.US)$ cost at 245, shall I sell😭😭

$PayPal (PYPL.US)$ you always amaze us😁🤩😋!

$Apple (AAPL.US)$ reported mixed fourth-quarter earnings, sending shares lower in after-hours trading.Apple's fourth-quarter revenues of $83.4 billion missed the consensus estimate, with iPhone revenues of $38.9 billion trailing the consensus estimate of $41.3 billion.With the "supply chain black cloud" impacting every sector, Apple's results showed the company isn't immune either. Supply chain constraint negatively impacted revenues, mainly that of iPhones, by about $6 billion.
However, analyst views this as transitory and it will in no way impact his long-term bullish view of Apple heading to a $3 trillion market cap in 2022.Apple will be running into a major iPhone 13 unit shortage for the holiday season if consumer demand keeps up at this pace, he added. This is purely a supply chain issue and not a demand issue for iPhones.

$Ocugen (OCGN.US)$
OCGN announced on 27/10 that it had submitted an Investigational New Drug Application (IND) to the US FDA to explore whether the effectiveness of Covaxin is applicable to the United States. This is also equivalent to OCGN starting to take the first step for the US BLA
According to the information provided by OCGN, assuming that the IND application is successfully approved, OCGN will formally conduct clinical trials in the United States, and then compare whether the results of the trials in the United States and India are the same.
OCGN said it hopes to complete the above tests in the first quarter of 2022.
According to FDA data, IND means that the drug has not been approved for sale/use in the United States.The FDA will approve the application within 30 days after receiving the IND application. If OCGN does not receive an objection from the FDA after 30 days, the trial can be conducted in the United States.
In addition, OCGN also issued a document reminding everyone that IND application is the first step in Phase 1 trials in the United States.
In conclusion, the IND application is the first step for OCGN to bring Covaxin to OCGN. The above information also reflects that OCGN has started to prepare for the BLA. Let me add one point here. Among the many BLA application conditions, the local test results in the United States must be an important part of whether the FDA approves the BLA.
In addition, everyone should be clear that this application is only an application for testing in the United States, not a formal application for the BLA. OCGN hopes to complete the test in early 2022.
Continue to wait patiently

$Ocugen (OCGN.US)$ maybe they add EUL for kids as well for Covaxin! makes it easier to compensate for all the delayes they have caused!

$Ocugen (OCGN.US)$ There is no other go but to approve this one. BB has been securing number of vaccine approvals from WHO in past and so this will also come. The vaccine is being administered in India for almost a year now, they have superb efficacy and data in place, and there is an ongoing requirement in the whole world. This will be APPROVED!